3 February 2022
The PrIMAVeRa consortium was privileged to attend an exciting online workshop hosted by Work Package 2 (WP2) leader -Technical University of Denmark (DTU)- on the 27th and 28th of January 2022. Twelve organisations participated in the workshop including European Vaccine Initiative (EVI), University Medical Center Utrecht (UMCU), University of Geneva (UNIGE), Institute of Health Carlos III (ISCIII), Ares Genetics GmbH (Ares), Eberhard Karls Universität Tübingen (EKUT), Université Grenoble Alpes (UGA), UK Health Security Agency (UKHSA), Hospital of Lithuanian University of Health Sciences Kauno Klinikos (KK), GlaxoSmithKleine (GSK), Pfizer and Janssen Vaccines & Prevention BV (Janssen).
The two-day workshop consisted of nine agenda items which included an overview of WP2, the presentation and discussion of antimicrobial resistance (AMR) case studies, the review of a draft of AMR protocol, and work plans and alignment of possible synergies amongst work packages.
Workshop highlights and overview:
During the first day, Professor Tine Hald, a WP2 contributor from DTU, explained the objectives of WP2. It’s main goal is to develop mathematical models for assessing the impact of various treatment and prevention strategies to reduce the burden of AMR. Case studies on prioritised pathogens (particularly Escherichia coli, MRSA and Pseudomonas aeruginosa) were presented by Dr Jeroen Geurtsen, from Janssen, and Dr Venanzio Vella, from GSK.
During the second day of the workshop, in separate break-out rooms, partners and attendees comprehensively discussed the case studies on the priority pathogens and gave feedback during a plenary session highlighting patient sub-groups, incidence and mortality, transmission cycles, resistance patterns, infection types and known prevention strategies including vaccines and monoclonal antibodies readily available or in the pipeline.
The productive and valuable event will further inform the development of suitable mathematical models for these and other priority AMR pathogens in Europe, in alignment with the PrIMAVeRa consortium objectives.
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 101034420. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
This communication reflects the author´s view and neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained herein.